akusherstvoObstetrics, Gynecology and ReproductionАкушерство, Гинекология и Репродукция2313-73472500-3194IRBIS LLC10.17749/2313-7347.2016.10.2.053-065akusherstvo-346Research ArticleCLINICAL LECTURESКЛИНИЧЕСКИЕ ЛЕКЦИИEPITHELIAL OVARIAN CANCER. CLINICAL LECTUREЭПИТЕЛИАЛЬНЫЙ РАК ЯИЧНИКОВ. КЛИНИЧЕСКАЯ ЛЕКЦИЯСолоповаА. Е.SolopovaA. E.

Солопова Алина Евгеньевна – кандидат медицинских наук, доцент кафедры лучевой диагностики и лучевой терапии лечебного факультета. 

Адрес: ул. Трубецкая, 8, стр. 2, Москва, Россия, 119991.

Solopova Alina Evgenievna – docent at the Department of Radiology. 

Address: ul. Trubetskaya, 8-2, Moskva, Russia, 119991.

dr.solopova@mail.ruЧащинА. А.ChashchinA. A.

Чащин Александр Андреевич – ординатор кафедры онкологии и радиотерапии ИПО. 

Адрес: ул. Трубецкая, 8, стр. 2, Москва, Россия, 119991.

Chashchin Alexander Andreevich – resident of Department of Oncology and Radiation Therapy.

Address: ul. Trubetskaya, 8-2, Moskva, Russia, 119048. 

alexchashchin@gmail.comСолоповаА. Г.SolopovaA. G.

Солопова Антонина Григорьевна – доктор медицинских наук, профессор кафедры акушерства и гинекологии медико-профилактического факультета. 

Адрес: ул. Трубецкая, 8, стр. 2, Москва, Россия, 119991.

Solopova Antonina Grigorevna – MD, Professor of Department of Obstetrics and Gynecology. 

Address: ul. Trubetskaya, 8-2, Moskva, Russia, 119048. 

antoninasolopova@yandex.ruМакацарияА. Д.MakatsariyaA. D.

Макацария Александр Давидович – доктор медицинских наук, член-корреспондент РАН, профессор, заведующий кафедрой акушерства и гинекологии медико-профилактического факультета. 

Адрес: ул. Трубецкая, 8, стр. 2, Москва, Россия, 119991.

Makatsariya Aleksandr Davidovich – MD, corresponding member of the Russian Academy of Sciences, Professor, Head of the Department of Obstetrics and Gynecology, Faculty of Medical and Preventive. 

Address: ul. Trubetskaya, 8-2, Moskva, Russia, 119048. 

Первый Московский государственный медицинский университет имени И.М. СеченоваРоссияI.M. Sechenov First Moscow State Medical UniversityRussian Federation2016301020161035365Copyright © Solopova A.E., Chashchin A.A., Solopova A.G., Makatsariya A.D., 20162016Солопова А.Е., Чащин А.А., Солопова А.Г., Макацария А.Д.Solopova A.E., Chashchin A.A., Solopova A.G., Makatsariya A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gynecology.su/jour/article/view/346

About 90 percent of ovarian cancers are epithelial tumors. High mortality rates, the lack of effective methods for early diagnosis and treatment make of the ovarian cancer a relevant problem for modern oncology. Only a wide application of clinical guidelines developed by professional societies based on the principles of evidence-based medicine could improve prognosis for that group of patients. This article attempts to summarize the experience of the world's leading centers for the fight against ovarian cancer of epithelial origin and offer solutions relevant to everyday clinical practice.

Опухоли яичников эпителиального происхождения составляют до 90% новообразований данного органа. Высокие показатели летальности, отсутствие эффективных методов ранней диагностики и лечения делают рак яичников актуальной проблемой современной онкологии. Основной стратегией, позволяющей добиться улучшения прогноза для пациенток, страдающих данной патологией, является повсеместное внедрение в практику клинических рекомендаций, разработанных профессиональными сообществами на основании принципов доказательной медицины. В настоящей статье сделана попытка обобщить опыт ведущих мировых центров по борьбе с раком яичников эпителиального происхождения и предложить решения, актуальные для повседневной клинической практики.

рак яичниковскринингтехнологии визуализацииМРТоптимальная циторедукцияovarian cancerscreeningimaging technologiesMRIoptimal debulking surgeryReferencesАксель Е.М. Статистика злокачественных новообразований женской половой сферы. Онкогинекология. 2012; 1: 18-23.Aksel' E.M. Onkoginekologiya. 2012; 1: 18-23.Давыдов М.И. Клинические рекомендации по диагностике и лечению больных раком яичников, маточной трубы или первичным раком брюшины. Ассоциация онкологов России. Москва. 2014 г. http://oncologyassociation. ru/docs/recomend/ may2015/2/57vz-rek.pdf. Дата обращения: 01.06.2016.Davydov M.I. Clinical guidelines for the diagnosis and treatment of patients with ovarian cancer, fallopian tube or primary peritoneal cancer. Russian Association of Oncologists. Moscow [Klinicheskie rekomendatsii po diagnostike i lecheniyu bol'nykh rakom yaichnikov, matochnoi truby ili pervichnym rakom bryushiny. Assotsiatsiya onkologov Rossii. Moskva. 2014 (in Russian)]. URL: http://oncology-association.ru/docs/ recomend/may2015/2/57vz-rek.pdf. Accessed: 01.06.2016.Давыдов М.И., Чиссов В.И. Онкология. Национальное руководство. Краткое издание. М. 2014.Davydov M.I., Chissov V.I. Oncology. National leadership. Short edition [Onkologiya. Natsional'noe rukovodstvo. Kratkoe izdanie (in Russian)]. Moscow. 2014.Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2013 г. (заболеваемость и смертность). М. 2015; 250 с.Kaprin A.D., Starinskii V.V., Petrova G.V. Malignancies in Russia in 2013 (morbidity and mortality) [Zlokachestvennye novoobrazovaniya v Rossii v 2013 g. (zabolevaemost' i smertnost') (in Russian)]. Moscow. 2015; 250 s.Рогожин В.А. МРТ в гинекологической практике. REJR. 2012; 2 (3): 27-40.Rogozhin V.A. REJR. 2012; 2 (3): 27-40.Balmana J., Diez O., Rubio I.T., Cardoso F. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2011; 22 (6): vi31-vi34.Balmana J., Diez O., Rubio I.T., Cardoso F. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2011; 22 (6): vi31-vi34.Bell D. et al. Integrated Genomic Analyses of Ovarian Carcinoma. Nature. 2011; 474 (7353): 609-615.Bell D. et al. Integrated Genomic Analyses of Ovarian Carcinoma. Nature. 2011; 474 (7353): 609-615.Borley J., Wilhelm-Benartzi C. et al. Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer. BJOG. 2015 May; 122 (6): 843-9.Borley J., Wilhelm-Benartzi C. et al. Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer. BJOG. 2015 May; 122 (6): 843-9.Cannistra S.A. Cancer of the Ovary. NEJM. 2004; 351: 2519-29.Cannistra S.A. Cancer of the Ovary. NEJM. 2004; 351: 2519-29.Cass I., Li A.J., Runowicz C.D. et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol. 2001; 80: 56-61.Cass I., Li A.J., Runowicz C.D. et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol. 2001; 80: 56-61.Catheleine M.G., van Driel et al. Stopping ovarian cancer screening in BRCA1/2 mutation carriers: Effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens. Maturitas. 2015; 80: 318-322.Catheleine M.G., van Driel et al. Stopping ovarian cancer screening in BRCA1/2 mutation carriers: Effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens. Maturitas. 2015; 80: 318-322.Chen Y.M., Chen T., Zee C.S. et al. Is there an impact of 18F-FDG PET/CT on the surveillance and clinical management of recurrent ovarian cancer? Research based on a large sample in a single PET/CT center. Nucl Med Commun. 2014 Apr; 35 (4): 347-52.Chen Y.M., Chen T., Zee C.S. et al. Is there an impact of 18F-FDG PET/CT on the surveillance and clinical management of recurrent ovarian cancer? Research based on a large sample in a single PET/CT center. Nucl Med Commun. 2014 Apr; 35 (4): 347-52.Chi D.S., Musa F., Dao F., Zivanovic O. et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012 Jan; 124 (1): 10-4.Chi D.S., Musa F., Dao F., Zivanovic O. et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012 Jan; 124 (1): 10-4.Chittenden B.G., Fullerton G., Maheshwari A., Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online. 2009; 19: 398.Chittenden B.G., Fullerton G., Maheshwari A., Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online. 2009; 19: 398.Cibula David et al. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev. Anticancer Ther. 2011; 11 (8): 1197-1207.Cibula David et al. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev. Anticancer Ther. 2011; 11 (8): 1197-1207.Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal Of Cancer. 2009; 45: 228-247.Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal Of Cancer. 2009; 45: 228-247.Forstner Rosemarie, Meissnitzer Matthias W., Schlattau Alexander & Spencer John A. MRI in ovarian cancer. Imaging Med. 2012; 4 (1): 59-75.Forstner Rosemarie, Meissnitzer Matthias W., Schlattau Alexander & Spencer John A. MRI in ovarian cancer. Imaging Med. 2012; 4 (1): 59-75.Fujiwara H., Suzuki M. et al. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. Tumor Biol. 2015; 36: 1045-1053.Fujiwara H., Suzuki M. et al. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. Tumor Biol. 2015; 36: 1045-1053.Gao J., Yang X., Zhang Y. Systematic lymphadenectomy in the treatment of epithelial ovarian cancer: a meta-analysis of multiple epidemiology studies. Jpn J Clin Oncol. 2015 Jan; 45 (1): 49-60.Gao J., Yang X., Zhang Y. Systematic lymphadenectomy in the treatment of epithelial ovarian cancer: a meta-analysis of multiple epidemiology studies. Jpn J Clin Oncol. 2015 Jan; 45 (1): 49-60.Gates M.A. et al. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol. 2010 Jan; 171 (1): 45-53.Gates M.A. et al. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol. 2010 Jan; 171 (1): 45-53.Griffin Nyree et al. Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique? EurRadiol. 2009; 19: 230-235.Griffin Nyree et al. Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique? EurRadiol. 2009; 19: 230-235.Gusehet S.H. et al. Transitional cell carcinoma of the ovary: A case-control study. Gynecologic Oncology. 2014; 132: 649-653.Gusehet S.H. et al. Transitional cell carcinoma of the ovary: A case-control study. Gynecologic Oncology. 2014; 132: 649-653.Hebel C.B., Behrendt F.F. et al. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer. Eur J Radiol. 2014 Mar; 83 (3): 463-7.Hebel C.B., Behrendt F.F. et al. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer. Eur J Radiol. 2014 Mar; 83 (3): 463-7.Heidemann L.N., Hartwell D., Heidemann C.H., Jochumsen K.M. The relation between endometriosis and ovarian cancer – a review. Acta Obstet Gynecol Scand 2014; 93: 20-31.Heidemann L.N., Hartwell D., Heidemann C.H., Jochumsen K.M. The relation between endometriosis and ovarian cancer – a review. Acta Obstet Gynecol Scand. 2014; 93: 20-31.Iyer V.R, Lee S.I. MRI, CT, and PET/CT for Ovarian Cancer Detection and adnexal Lesion Characterization. AJR. 2010 Feb; 194 (2): 311-21.Iyer V.R, Lee S.I. MRI, CT, and PET/CT for Ovarian Cancer Detection and adnexal Lesion Characterization. AJR. 2010 Feb; 194 (2): 311-21.Jaaback K. and Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2011; CD005340.Jaaback K. and Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2011; CD005340.Jung D.C., Kang S., Kim M.J., Park S.Y. et al. Multidetector CT predictors of incomplete resection in primary cytoreduction of patients with advanced ovarian cancer. Eur Radiol. 2010; 20: 100-107.Jung D.C., Kang S., Kim M.J., Park S.Y. et al. Multidetector CT predictors of incomplete resection in primary cytoreduction of patients with advanced ovarian cancer. Eur Radiol. 2010; 20: 100-107.Katsumata N., Yasuda M., Isonishi S., et al. Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. J Clin Oncol. 2012; 30 (15): Abstract 5003.Katsumata N., Yasuda M., Isonishi S., et al. Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. J Clin Oncol. 2012; 30 (15): Abstract 5003.Katsumata N., Yasuda M., Takahashi F., et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, openlabel, randomised controlled trial. Lancet. 2009; 374 (9698): 1331-8.Katsumata N., Yasuda M., Takahashi F., et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009; 374 (9698): 1331-8.Kehoe S., Hook J., Nankivell M., Jayson G.C. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. The Lancet. 2015 Jul 18; 386 (9990): 249-57.Kehoe S., Hook J., Nankivell M., Jayson G.C. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. The Lancet. 2015 Jul 18; 386 (9990): 249-57.Khaliquea S., Hookb J.M., Ledermann J.A. Maintenance therapy in ovarian cancer. Curr Opin Oncol. 2014; 26: 521-528.Khaliquea S., Hookb J.M., Ledermann J.A. Maintenance therapy in ovarian cancer. Curr Opin Oncol. 2014; 26: 521-528.Kurman R.J. The Origin and Pathogenesis of Epithelial Ovarian Cancer – a Proposed Unifying Theory. Am J SurgPathol. 2010 Mar; 34 (3): 433-443.Kurman R.J. The Origin and Pathogenesis of Epithelial Ovarian Cancer – a Proposed Unifying Theory. Am J SurgPathol. 2010 Mar; 34 (3): 433-443.Kyriazi S., Kaye Stan B. and Nandita M. de Souza Imaging ovarian cancer and peritoneal metastases – current and emerging techniques. Nature reviews. 2010 Jul; 7 (7): 381-93.Kyriazi S., Kaye Stan B. and Nandita M. de Souza Imaging ovarian cancer and peritoneal metastases – current and emerging techniques. Nature reviews. 2010 Jul; 7 (7): 381-93.La Vecchia Carlo Ovarian cancer: epidemiology and risk factors. European Journal of Cancer Prevention. 2016 Jan; Epub ahead of print.La Vecchia Carlo Ovarian cancer: epidemiology and risk factors. European Journal of Cancer Prevention. 2016 Jan; Epub ahead of print. 2014. https://canceraustralia.gov.au/sites/ default/files/guidelines/first-line_chemotherapy_ for_the_treatment_of_women_with_ epithelial_ovarian_cancer.pdf. Дата обращения: 01.06.2016.Ledermann J. A., Raja F. A. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2013. Ann Oncol. 2013; 24 (6): vi24-vi32.Ledermann J. A., Raja F. A. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2013. Ann Oncol. 2013; 24 (6): vi24-vi32.MacKintosh M.L., Rahim R., et al. CT scan does not predict optimal debulking in stage III-IV epithelial ovarian cancer: a multicentre validation study. J ObstetGynaecol. 2014 Jul; 34 (5): 424-8.MacKintosh M.L., Rahim R., et al. CT scan does not predict optimal debulking in stage III-IV epithelial ovarian cancer: a multicentre validation study. J ObstetGynaecol. 2014 Jul; 34 (5): 424-8.Medeiros L.R. Accuracy of Ultrasonography With Color Doppler in Ovarian Tumor: A Systematic Quantitative Review. International Journal of Gynecological Cancer. 2009 Feb; 19 (2): 230-236.Medeiros L.R. Accuracy of Ultrasonography With Color Doppler in Ovarian Tumor: A Systematic Quantitative Review. International Journal of Gynecological Cancer. 2009 Feb; 19 (2): 230-236.Menon Usha et al. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J ClinOncol. 2015 Jun; 33 (18): 2062-71.Menon Usha et al. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J ClinOncol. 2015 Jun; 33 (18): 2062-71.Mitchell D.G., Javitt M.C., Glanc P., Bennet G.L. et al. ACR Appropriateness Criteria: Staging and Follow-up of Ovarian Cancer. J Am CollRadiol. 2013; 10: 822-827.Mitchell D.G., Javitt M.C., Glanc P., Bennet G.L. et al. ACR Appropriateness Criteria: Staging and Follow-up of Ovarian Cancer. J Am CollRadiol. 2013; 10: 822-827.Morgan R.J., Armstrong D.K., Alvarez R.D, Bakkum-Gamez J.N. et al NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2.2015. https:// www.nccn.org/professionals/physician_gls/ pdf/ovarian.pdf. Дата обращения: 01.06.2016.Morgan R.J., Armstrong D.K., Alvarez R.D, Bakkum-Gamez J.N. et al NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2.2015. URL: https://www.nccn.org/ professionals/physician_gls/pdf/ovarian.pdf. Accessed: 01.06.2016.Phuong L. Mai et al. A Major Step Forward for BRCA1/2-Related Cancer Risk Management. Journal Of Clinical Oncology. 2014; 2014 May; 32 (15): 1531-3.Phuong L. Mai et al. A Major Step Forward for BRCA1/2-Related Cancer Risk Management. Journal Of Clinical Oncology. 2014; 2014 May; 32 (15): 1531-3.Prat Jaime and FIGO Committee on Gynecologic Oncology FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015 Apr; 26 (2): 87-89.Prat Jaime and FIGO Committee on Gynecologic Oncology FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015 Apr; 26 (2): 87-89.Rizzuto I., Behrens R.F., Smith L.A. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. The Cochrane Library 2013, Issue 8.Rizzuto I., Behrens R.F., Smith L.A. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. The Cochrane Library 2013, Issue 8.Rustin G.J.S., Vergote I., Eisenhauer E., Pujade-Lauraine E. et al. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011; 21: 419-423.Rustin G.J.S., Vergote I., Eisenhauer E., Pujade-Lauraine E. et al. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011; 21: 419-423.Seward S.M., Winer I. Primary Debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Cancer Metastasis Rev. 2015; 34: 5-10.Seward S.M., Winer I. Primary Debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Cancer Metastasis Rev. 2015; 34: 5-10.Spencer J.A. ESUR guidelines for MR imaging of the sonographically indeterminate adnexal mass: an algorithmic approach. EurRadiol. 2010; 20: 25-35.Spencer J.A. ESUR guidelines for MR imaging of the sonographically indeterminate adnexal mass: an algorithmic approach. EurRadiol. 2010; 20: 25-35.Steer Ch. et al. First-line chemotherapy for the treatment of women with epithelial ovarian cancer Recommendations for the use of firstline chemotherapy for the treatment of women with epithelial ovarian cancer. Cancer Australia. 2014. https://canceraustralia.gov.au/sites/ default/files/guidelines/first-line_chemotherapy_ for_the_treatment_of_women_with_ epithelial_ovarian_cancer.pdf. Дата обращения: 01.06.2016.Steer Ch. et al. First-line chemotherapy for the treatment of women with epithelial ovarian cancer Recommendations for the use of firstline chemotherapy for the treatment of women with epithelial ovarian cancer. Cancer Australia. 2014. URL: https://canceraustralia.gov.au/ sites/default/files/guidelines/first-line_ chemotherapy_for_the_treatment_of_ women_with_epithelial_ovarian_cancer.pdf. Accessed: 01.06.2016.Stewart L.M., Holman C.D., Aboagye-Sarfo P., et al. In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. Gynecol Oncol. 2013; 128: 260. 49. Stiekema A. et al. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin. Gynecologic Oncology. 2015 Mar; 136 (3): 562-6.Stewart L.M., Holman C.D., Aboagye-Sarfo P., et al. In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. Gynecol Oncol. 2013; 128: 260.Svolgaard O., Lidegaard O., Nielsen M.L. Lymphadenectomy in surgical stage I epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2014 Mar; 93 (3): 256-60.Stiekema A. et al. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin. Gynecologic Oncology. 2015 Mar; 136 (3): 562-6.Thabet Ashraf et al. Image-Guided Ovarian Mass Biopsy: Efficacy and Safety. J VascInterv Radiol. 2014; 25: 1922-1927.Svolgaard O., Lidegaard O., Nielsen M.L. Lymphadenectomy in surgical stage I epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2014 Mar; 93 (3): 256-60.Thomassin-Naggara I., Balvay D. et al. Added Value of Assessing Adnexal Masses with Advanced MRI Techniques. BioMed Research International. 2015; Article ID 785206, 10 pages.Thabet Ashraf et al. Image-Guided Ovarian Mass Biopsy: Efficacy and Safety. J VascInterv Radiol. 2014; 25: 1922-1927.Tworoger S.S., Fairfield K.M., Colditz G.A., et al. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol. 2007; 166: 894.Thomassin-Naggara I., Balvay D. et al. Added Value of Assessing Adnexal Masses with Advanced MRI Techniques. BioMed Research International. 2015; Article ID 785206, 10 pages.Van Gorp Toon et al Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. European Journal of Cancer. 2012; 48: 1649-1656.Tworoger S.S., Fairfield K.M., Colditz G.A., et al. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol. 2007; 166: 894.Vergote I., Trope C.G., Amant F. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363: 943-953.Van Gorp Toon et al Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. European Journal of Cancer. 2012; 48: 1649-1656.Wagner Uwe, Harter Philipp et al. S3-Leitline Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren 2013, 103s. http://www.agoonline. de/fileadmin/downloads/leitlinien/ovar/ S3-Ovarialkarzinom-OL-Langversion.pdf. Дата обращения: 30.06.2016.Vergote I., Trope C.G., Amant F. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363: 943-953.Wilkinson N., Pathology of the Ovary, Fallopian Tube and Peritoneum. London: Sprienger-Verlag. 2014; 524 р.Wagner Uwe, Harter Philipp et al. S3-Leitline Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren 2013, 103s. http://www.agoonline. de/fileadmin/downloads/leitlinien/ovar/ S3-Ovarialkarzinom-OL-Langversion.pdf. Accessed: 30.06.2016.Wilkinson N., Pathology of the Ovary, Fallopian Tube and Peritoneum. London: Sprienger-Verlag. 2014; 524 r.Wilkinson N., Pathology of the Ovary, Fallopian Tube and Peritoneum. London: Sprienger-Verlag. 2014; 524 r.

The authors declare that there are no conflicts of interest present.